Metrics as of 10/15/2026, 04:09 PM (Berlin time), refresh in progress.
Perspective Therapeutics Stock
Perspective Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Johan Spoor
- Employees
- 165
- Market cap
- $268 M
- IPO
- 10/11/2005
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions,…
Perspective Therapeutics stock: price history
1D
+1.8%
1W
-15.9%
1M
-16.5%
6M
-46.5%
YTD
-17.1%
1Y
-54.2%
2Y
-81.8%
5Y
-63.3%
10Y
-67.4%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~12% weaker price swings than usual
Ask the agents about Perspective Therapeutics
Analyst assessment of Perspective Therapeutics
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 07/10/2026
Perspective Therapeutics stock metrics
P/E
-1.5
P/B
0.53
EV/EBITDA
-1.94
RETURN ON EQUITY
-8.3%
NET MARGIN
-33,069.1%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
62.0%
FLOAT SHARES
70,817,409
AVG. DAILY VOLUME (30D)
2,149,346
Insider transactions (SEC)
Lantheus Alpha Therapy, LLC
Lantheus Alpha Therapy, LLC
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Perspective Therapeutics stock
What does Perspective Therapeutics do?
Perspective Therapeutics, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Johan Spoor, the company employs around 165 people.
The IPO was on 10/11/2005; the stock trades on AMEX under the ticker CATX.
What do analysts say about Perspective Therapeutics stock?
12 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$11.00, ranging from US$11.00 to US$11.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Perspective Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -12% stronger than usual.
Does Perspective Therapeutics pay a dividend?
No, Perspective Therapeutics currently does not pay a dividend.
Which stocks are comparable to Perspective Therapeutics?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Perspective Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Perspective Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.